Lepu Biopharma Co., Ltd. (2157.HK), Friday announced a CDMO Services Framework Agreement with Lepu Medicals regarding GLP-1 and related products.
The agreement aims to ensure continued procurement of activities between the companies.
The agreement will be effective from January 1, 2026, to December 31, 2026, with an option to extend it further depending upon legal and regulatory requirements.
Lepu Biopharma's stock closed at HK$5.690, down 1.043 percent on the Hong Kong Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.